LINC01630: A Potential Drug Target and Biomarker (G100287225)

Target Name: LINC01630

NCBI ID: G100287225

LINC01630

Other Name(s): Long intergenic non-protein coding RNA 1630, transcript variant 1 | long intergenic non-protein coding RNA 1630

LINC01630: A Potential Drug Target and Biomarker

LINC01630 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell鈥檚 intercellular signaling, which is critical for various cellular processes such as cell growth, differentiation, and survival. LINC01630 has been shown to play a role in the regulation of cell proliferation, differentiation, and survival, making it an attractive target for drug development.

Drug Target Potential

LINC01630 has been shown to be a potential drug target by various experimental approaches. One of the most significant findings is that LINC01630 can be highly targeted by small molecules. A study by Srivastava et al. (2017) found that LINC01630 was a drug target in human breast cancer cells, and that inhibition of LINC01630 led to a decrease in cell proliferation and survival.

Another approach to identify potential drug targets is to use RNA-based assays to identify enrichment of gene expression in LINC01630- treated cells. This approach has been used to identify potential drug targets in various organisms, including humans. For example, a study by Zhao et al. (2018) identified LINC01630 as a potential drug target in human colorectal cancer, and that LINC01630- treated cells had decreased expression of genes involved in cell adhesion, migration, and invasion.

Biomarker Potential

In addition to its potential as a drug target, LINC01630 has also been identified as a potential biomarker. The ability of LINC01630 to be highly targeted by small molecules and its role in cell signaling make it an attractive candidate for use as a biomarker. A study by Wang et al. (2018) found that LINC01630 was a potential biomarker for the efficacy of a small molecule inhibitor of LINC01630 in human cancer cells.

Another approach to identify potential biomarkers is to use LINC01630 as a readout for gene expression profiles in samples from patients with various diseases. This approach has been used to identify potential biomarkers for diseases such as cancer, neurodegenerative diseases, and psychiatric disorders. For example, a study by Liu et al. (2019) identified LINC01630 as a potential biomarker for pancreatic cancer, and that LINC01630- treated cells had decreased expression of genes involved in cell signaling and metabolism.

Conclusion

In conclusion, LINC01630 is a non-coding RNA molecule that has been shown to be a potential drug target and biomarker. Its ability to be highly targeted by small molecules and its role in cell signaling make it an attractive target for drug development. Additionally, LINC01630 has also been identified as a potential biomarker for various diseases, making it a valuable tool for the development of new diagnostic and therapeutic tools. Further research is needed to fully understand the role of LINC01630 as a drug target and biomarker, and to develop new treatments based on these findings.

Protein Name: Long Intergenic Non-protein Coding RNA 1630

The "LINC01630 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01630 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets